Terminated PHASE2 INTERVENTIONAL 2-arm NCT00298272

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis

Sponsor: Biogen

Conditions Rheumatoid Arthritis

Interventions Adalimumab Etanercept Folate IDEC-C2B8 (rituximab) Methotrexate Methylprednisolone Placebo

Updated 8 times since 2017 Last updated: Aug 27, 2015 Started: May 31, 2006 Primary completion: Apr 30, 2009 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decided to end long term extension phase for business reasons unrelated to safety.

Other terminated trials from Biogen

See all terminations from Biogen

Other Rheumatoid Arthritis trials with similar outcome

Browse all Rheumatoid Arthritis trials

This PHASE2 trial investigates Rheumatoid Arthritis and is currently terminated or withdrawn. Biogen leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Genentech, Inc.
Hoffmann-La Roche

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boise, United States , Burlington, United States , Chardon, United States , Dallas, United States , Duncansville, United States , Houston, United States , Huntsville, United States , Jupiter, United States , Kalamazoo, United States , Mayfield Village, United States and 8 more locations